Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Nam	e of entity		ABN/ARSN
Sig	ma Pharmaceuticals Limited		15 088 417 403
We	(the entity) give ASX the following	information.	
Inf	ormation about buy-back		
1	Type of buy-back	On-market buy-back	
2	Date Appendix 3C was given to ASX		3D dated 18 November
	tal of all shares/units bought we been received, before, and	on, previous day	_
			Previous day
		on, previous day	_
hav	Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been	on, previous day Before previous day	Previous day

Before previous day		ay F	Previous day		
Lighagt	prioc	noid:	Lighagt	nrina	noi

5 If buy-back is an on-market buy-

Highest \$0.8700	price	paid:	Highest price paid: \$0.8300
Lowest \$0.5600	price	paid:	Lowest price paid: \$0.8200
*******			Highest price allowed under rule 7.33: \$0.8939

How many shares/units may still be bought back?

6	If the company/trust has disclosed					
	an intention to buy back a					
	maximum number of shares/units					
	- the remaining number of					
	shares/units to be bought back					

Date: 4 December 2015

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here: (Director/Company secretary)

Print name: JEFF SELLS

== == == == ==